Lineagen Business Overview and Operations

Lineagen is a leading genetic diagnostics company that specializes in the development and commercialization of genetic tests for rare genetic disorders. The company's tests focus on detecting genetic mutations that cause rare conditions.

Lineagen's genetic tests are designed to be used by healthcare professionals to aid in the diagnosis and management of rare genetic disorders. These tests are typically ordered by doctors to help identify the underlying cause of a patient's symptoms.

Lineagen's business model is built around the commercialization of its genetic tests, which are used to diagnose and manage rare genetic disorders. The company has developed a range of tests that are designed to be used in a clinical setting.

Lineagen's genetic tests are designed to be accurate and reliable, with high sensitivity and specificity.

You might like: Deseret News Publishing Company

Lineagen is a US-based company that has been active since its incorporation on December 31, 1999.

The company is associated with a single legal entity, Lineagen Inc, which has a unique identifier of 204508128.

Lineagen Inc has a relatively small employee count, with 40 staff members as of December 31, 2022.

Here's a brief overview of the key information about Lineagen Inc:

In this section, we'll take a closer look at the legal entities associated with Lineagen.

One of the key pieces of information about Lineagen is that it has a legal entity registered in the United States.

The legal entity name is LINEAGEN INC, with a company identification number (CIN) of 204508128.

It was incorporated on December 31, 1999, marking the beginning of the company's journey.

LINEAGEN INC is currently active, indicating that it is still operational.

As of December 31, 2022, the company has a relatively small team of 40 employees.

Here's a summary of the key facts about LINEAGEN INC in a table:

This information can be useful for anyone looking to learn more about Lineagen's business operations.

Lineagen has received a total of $66.9M in funding across 7 rounds.

Its first funding round was on June 22, 2010. Lineagen's latest funding round was a Series C round on January 26, 2015, which raised $12.2M.

Three investors participated in Lineagen's latest funding round, led by Health Quest Capital. The company has 12 institutional investors, including Sanderling Ventures, Prairiegold Venture Partners, and Mesa Verde Venture Partners.

Here's a breakdown of Lineagen's funding rounds:

Lineagen has a strong market presence in the genetic testing industry. They offer genetic testing for inherited eye diseases, specifically for conditions such as Leber congenital amaurosis and cone-rod dystrophy.

Their genetic testing services are designed to identify genetic mutations that cause these conditions, allowing for earlier diagnosis and treatment. This can help families make informed decisions about their reproductive health.

Lineagen's testing services are available to patients and healthcare providers through their website and network of laboratories. Their team of genetic counselors and laboratory professionals work together to provide accurate and reliable test results.

Lineagen's genetic testing services are designed to be accessible and affordable, with payment options available to help make testing more feasible for patients.

Lineagen has made significant strides in research and development, particularly in the area of autism spectrum disorder (ASD). The company recently completed a 9,000-person research study to confirm novel genetic variants associated with ASD.

This study was a collaboration between Lineagen and other institutions, including The Children’s Hospital of Philadelphia (CHOP) and the University of Utah. Hakon Hakonarson, MD, PhD, and Mark F. Leppert, PhD, led the research teams at CHOP and the University of Utah, respectively.

The study aimed to identify novel copy number genetic variants and next-generation sequence variants associated with ASD. The findings of this study have been incorporated into Lineagen's FirstStepDx genetic testing service.

In partnership with Affymetrix, Lineagen has developed a next-generation FirstStepDx service that combines advanced genetic testing with genetic counseling. This service is designed to accelerate and enhance the diagnostic evaluation of individuals with ASD, developmental delay, and intellectual disability.

Lineagen was granted an exclusive commercial license to the novel genetic variants discovered in the study. This license was part of a broader collaboration with CHOP and the University of Utah to improve our understanding of the genetic contributors to ASD.